Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 5/20 | 0.31 |
| ▸ | RAB9A | P51151 | 5/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.31 |
| ▸ | STAT1 | P42224 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21395812 | 0.80 | — | — | |
| SCHEMBL19783689 | 0.73 | LMNA (0.45) | GAASMN1; SMN2ALDH1A1MAPK1KMT2A | |
| SCHEMBL19783010 | 0.71 | KMT2A (0.32) | MAPTGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19782781 | 0.70 | MAPT (0.38) | MAPTGAAALDH1A1ALOX15PKM | |
| SCHEMBL19783461 | 0.70 | NSD1 (0.37) | MAPTGAANPC1ALDH1A1GPR35 | |
| SCHEMBL19783026 | 0.67 | PDE10A (0.32) | KMT2A | |
| SCHEMBL19782660 | 0.67 | F9 (0.37) | MAPTGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19782420 | 0.66 | F9 (0.40) | MAPTGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19782970 | 0.65 | LMNA (0.44) | MAPTGAASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL31341995 | 0.64 | PIK3CA (0.43) | MAPTGAANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, PF4 | MAPT 1432/4885PTPN1 2174/4885GAA 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.